US Stock MarketDetailed Quotes

LGVN Longeveron

Watchlist

2.090
-0.100-4.57%

Trading Oct 21 11:59 ET

30.01MMarket Cap-235P/E (TTM)

Longeveron Stock Forum

Clintzilla

Oct 19 09:23

$Longeveron (LGVN.US)$ people have no clue what this really is and can be.. although not legal in the State's yet to produce huge revenue, they are and have been making tremendous strides in the Bahamas and Japan, this is a true investor play meaning you put your big money in and leave it til 2029 or 2031 but for us with less bankroll or looking to grow your bankroll.. swing it from November to March.. let me know how it goes.. 2.20 is a steal..

f1ymetotheM00N

Oct 15 06:08

$Longeveron (LGVN.US)$

Jaguar8

Oct 14 08:12

NEWS

$Longeveron (LGVN.US)$
Longeveron® Lomecel-B™ Data in Alzheimer's Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24)
MIAMI, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that its submission entitled "Lomecel-B inhibition of MMP14 activity predicts Lomecel-B bioactivity in the treatment of mild Alzheimer's disease" ha...

Teddy123

Oct 9 11:35

Longeveron® Lomecel-B™ 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting

$Longeveron (LGVN.US)$
09/10/2024 - 21:05
MIAMI, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that its submission entitled “Long-term Tr...

Teddy123

Oct 7 09:48

Longeveron ® to Present at the UBS Virtual Organ Restoration and Cell Therapy Day

$Longeveron (LGVN.US)$
Longeveron ® to Present at the UBS Virtual Organ Restoration and Cell Therapy Day By Investing.com

103673643

Oct 4 00:21

$Longeveron (LGVN.US)$
How might Lomecel-B's approval influence other Alzheimer's treatments
If Lomecel-B receives FDA approval, it could significantly influence other Alzheimer's treatments in several ways:
1. **Market Dynamics**: Approval may shift market focus towards regenerative therapies, encouraging more investment and research in stem cell and regenerative medicine approaches for Alzheimer's, potentially leading to a broader range of treatment options.
2. **Competitive Pressure**: Esta...

103673643

Oct 4 00:17

$Longeveron (LGVN.US)$
if Fda approved what will happen
If the FDA approves Lomecel-B for Alzheimer's disease, several significant outcomes can be expected:
1. **Market Launch**: Lomecel-B would become available for prescription, providing a new treatment option for patients with mild Alzheimer's disease, potentially impacting the estimated $15.9 billion Alzheimer's treatment market by 2030[1].
2. **Increased Stock Value**: Approval could lead to a substantial increase in Longeveron's stock pr...